We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Enigma Diagnostics Announces a European Commission Award of EUR3 Million
News

Enigma Diagnostics Announces a European Commission Award of EUR3 Million

Enigma Diagnostics Announces a European Commission Award of EUR3 Million
News

Enigma Diagnostics Announces a European Commission Award of EUR3 Million

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Enigma Diagnostics Announces a European Commission Award of EUR3 Million"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Enigma Diagnostics has announced a EUR3 million award from the European Commission Framework 7 programme to the RANGER consortium. The award will fund the development and validation of a fully automated, low cost system for the rapid diagnosis of influenza infections and subtypes.

The RANGER consortium, which is coordinated by Enigma Diagnostics, comprises companies including Applied Biosystems, Sagentia, Tico Europe, Bruhn Newtech Group, Bioplastics BV and PERA who will contribute to the development of the instrument and assays.

The consortium also includes the Health Protection Agency, the UK's national reference laboratory for influenza diagnostics, and the Queen Sirikit National Institute of Child Health who will evaluate and validate the system.

The system will be based on Enigma's proprietary and fully-automated instrumentation technology, which integrates sample preparation with real-time polymerase chain reaction (PCR) to detect viral RNA in a full range of clinical samples. The simple-to-use, portable system will provide results direct to medical staff in a near-patient or out-reach environment in both the developed and developing world.

By providing laboratory standard, high specificity and sensitivity PCR results in a decentralized setting, the system will advance the diagnosis of early stage viral infections and the surveillance of disease outbreaks.

Enigma is also separately developing real-time PCR-based diagnostics systems targeting chlamydia, gonorrhoea and other sexually transmitted infections.

John McKinley, Chairman of Enigma Diagnostics, said: "The award of this grant and the strength of our consortium partners is a great endorsement of Enigma's technology. It is also a strategically important milestone for the company as it demonstrates the utility of our real time PCR in what is an extremely challenging area of diagnosis. We are confident we will be able to deliver a system that rapidly and simply delivers laboratory quality results at the point of care."

Advertisement